Kanabo Group PLC
LSE:KNB
Kanabo Group PLC
Kanabo Group Plc engages in the acquisition of a target company and business in the energy and industrial sectors. The firm is principally focused on distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for Cannabidiol (CBD) consumers. The company has developed a formula for sleep disorders (insomnia), three CBD formulations for Reload, Relax, and Repair, and the VapePod, which is a vaporization delivery system for cannabis extract. The firm's R&D lab is set up in the Weizmann Science Park. The firm's clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The firm is selling its initial products in Europe. The company is also engaged in conducting research and development (R&D) to develop cannabis oil formulas, medical-grade vaporizers, and various non-smoking consumption solutions.
Kanabo Group Plc engages in the acquisition of a target company and business in the energy and industrial sectors. The firm is principally focused on distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for Cannabidiol (CBD) consumers. The company has developed a formula for sleep disorders (insomnia), three CBD formulations for Reload, Relax, and Repair, and the VapePod, which is a vaporization delivery system for cannabis extract. The firm's R&D lab is set up in the Weizmann Science Park. The firm's clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The firm is selling its initial products in Europe. The company is also engaged in conducting research and development (R&D) to develop cannabis oil formulas, medical-grade vaporizers, and various non-smoking consumption solutions.
